<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03487432</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE Nr. BA00117</org_study_id>
    <nct_id>NCT03487432</nct_id>
  </id_info>
  <brief_title>A ComparIson of Strategies to PrepAre SeveRely CALCified Coronary Lesions</brief_title>
  <acronym>ISAR-CALC</acronym>
  <official_title>A ComparIson of Strategies to Prepare Severely Calcified Coronary Lesions - A Prospective Randomized Controlled Trial of Super High-Pressure NC PTCA Balloon Versus Scoring PTCA Balloon in Severely Calcified Coronary Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SIS Medical AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this prospective, multicenter, randomized, open-label trial is to evaluate
      the completeness of stent expansion following a strategy of lesion preparation with either a
      Super High-Pressure NC PTCA Balloon (OPN NC) or a Scoring PTCA Balloon (NSE Alpha) after
      unsuccessful lesion preparation with conventional NC balloon angioplasty in an
      angiographically well-defined group of patients with severely calcified coronary lesions
      (grade 3) undergoing coronary stent implantation (SYNERGY everolimus-eluting stent (EES)).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stent expansion index (SEI)</measure>
    <time_frame>intraprocedural</time_frame>
    <description>Stent expansion index (SEI), defined as minimum stent area divided by mean reference area in an optical coherence tomography (OCT) quantitative analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic Success</measure>
    <time_frame>intraprocedural</time_frame>
    <description>'Angiographic Success', defined as the achievement of residual angiographic stenosis &lt;30% of the target lesion in the presence of TIMI 3 flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>30 days</time_frame>
    <description>'Procedural Success`, defined as the achievement of angiographic success without any MACE, defined as cardiac death, target vessel related myocardial infarction and repeat revascularization (PTCA/PCI or coronary artery bypass graft [CABG])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Strategy Success</measure>
    <time_frame>intraprocedural</time_frame>
    <description>'Strategy Success' defined as procedural success using the assigned study device and stent, without requirement for lesion preparations with further devices (i.e. rotational atherectomy [RA])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute lumen gain,</measure>
    <time_frame>intraprocedural</time_frame>
    <description>Acute lumen gain, defined as minimal lumen diameter (MLD) post balloon angioplasty minus baseline MLD (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complementary lesion preparations</measure>
    <time_frame>intraprocedural</time_frame>
    <description>Number of complementary lesion preparations with further devices (i.e. rotational atherectomy [RA])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of vessel perforation</measure>
    <time_frame>intraprocedural</time_frame>
    <description>Rate of vessel perforation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure duration</measure>
    <time_frame>intraprocedural</time_frame>
    <description>Procedure duration in min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast volume</measure>
    <time_frame>intraprocedural</time_frame>
    <description>Contrast volume in mL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Calcified Coronary Artery Disease (Grade 3)</condition>
  <arm_group>
    <arm_group_label>OPN NC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving a Super High-Pressure NC PTCA Balloon (OPN NC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSE Alpha</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving a Scoring PTCA Balloon (NSE Alpha)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Super High-Pressure NC PTCA Balloon (OPN NC)</intervention_name>
    <description>Strategy of Super High-Pressure NC PTCA Balloon (OPN NC) after unsuccessful lesion preparation with conventional NC balloon angioplasty.</description>
    <arm_group_label>OPN NC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Scoring PTCA Balloon (NSE Alpha)</intervention_name>
    <description>Strategy of Scoring PTCA Balloon (NSE Alpha) after unsuccessful lesion preparation with conventional NC balloon angioplasty.</description>
    <arm_group_label>NSE Alpha</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age above 18 years and consentable;

          -  Persistent angina symptoms despite optimal medical therapy and/or evidence of
             inducible ischemia;

          -  Angiographically-proven coronary artery disease;

          -  De novo lesion in a native coronary artery;

          -  Target reference vessel diameter between 2.25 and 4.00 mm by visual estimation;

          -  Calcification of the target lesion as determined by angiography (grade 3);

          -  Unsuccessful lesion preparation (&lt;30% reduction of baseline diameter stenosis) with
             conventional NC balloon angioplasty

          -  Written informed consent.

        Exclusion Criteria:

          -  Myocardial infarction (within 1 week);

          -  Limited long-term prognosis due to other conditions;

          -  Target lesion is in a coronary artery bypass graft;

          -  Target lesion is an in-stent restenosis;

          -  Target lesion is aorto-ostial;

          -  Target vessel thrombus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Byrne, MD BCh PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salvatore Cassese, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tobias Rheude, MD</last_name>
    <phone>+491218</phone>
    <phone_ext>2985</phone_ext>
    <email>rheude@dhm.mhn.de</email>
  </overall_contact>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2018</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

